RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($) |
3 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|
Mar. 31, 2023 |
Mar. 31, 2022 |
Dec. 31, 2020 |
Dec. 31, 2022 |
|
| Related Party Transaction [Line Items] | ||||
| Research and development related expenses | $ 206,544 | $ 254,837 | ||
| IGL Pharma Inc [Member] | ||||
| Related Party Transaction [Line Items] | ||||
| Research and development related expenses | 0 | $ 9,355 | ||
| IGL Pharma Inc [Member] | Service [Member] | ||||
| Related Party Transaction [Line Items] | ||||
| Due to related party | 7,876 | $ 13,900 | ||
| Officers and Directors [Member] | ||||
| Related Party Transaction [Line Items] | ||||
| Proceeds from short-term notes payable | $ 45,500 | |||
| Debt Instrument, Interest Rate During Period | 10.00% | |||
| Short-term notes payable outstanding | $ 7,500 | $ 7,500 | ||
| IGL Pharma Inc [Member] | President [Member] | ||||
| Related Party Transaction [Line Items] | ||||
| Subsidiary, Ownership Percentage, Noncontrolling Owner | 1.00% | |||
| Salary and Wage, Officer, Excluding Cost of Good and Service Sold | $ 500 | |||
| X | ||||||||||
- Definition The average effective interest rate during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of liabilities classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|